Genetics of lipid disorders

Current Opinion in Cardiology

Volumn 25, Issue 3, 2010, Pages 238-242

  Pirruccello, James ^a,b,c   Kathiresan, Sekar ^a,b,c,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cholesterol; Genetics; Genome wide association; Lipids; Triglycerides

Indexed keywords

LIPID;

DRUG TARGETING; GENE IDENTIFICATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOME; HUMAN; HYPOTHESIS; LIPID BLOOD LEVEL; LIPOPROTEIN METABOLISM; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LIPID METABOLISM DISORDERS; LIPIDS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA;

EID: 77952242112     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e328338574d     Document Type: Review

References (20)

1. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117: e25-e146.
2. Kathiresan S, Manning A, Demissie S, et al. A genome-wide association study for blood lipid phenotypes in the Framingham Heart study. BMC Med Genet 2007; 8 (Suppl 1) : S17.
3. Lagace TA, Curtis DE, Garuti R, et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest 2006;116:2995-3005.
4. Abifadel M, Varret M, Rabes J, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003;34:154-156.
5. Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006;354:1264-1272.
6. Willard H. Genomic and personalized medicine. 1st ed. Amsterdam and Boston: Elsevier/Academic Press; 2009.
7. Diabetes Genetics Initiative of Broad Institute of Harvard and MIT LU; Saxena R, Voight BF, Lyssenko V, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007;316:1331-1336.
8. Kathiresan S, Willer CJ, Peloso GM, et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet 2009;41:56-65. Using GWA data from 19 840 individuals and targeted replication in up to 20 623 individuals, compelling statistical evidence is provided for 30 loci associated with LDL-C, HDL-C, and/or triglycerides.
9. Aulchenko YS, Ripatti S, Lindqvist I, et al. Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet 2009;41:47-55. Using GWA data from 22 562 individuals, compelling statistical evidence is provided for 22 loci associated with LDL-C, HDL-C, and/or triglycerides. Almost all of these loci overlap with the work of Kathiresan et al. [8"].
10. Kotowski IK, Pertsemlidis A, Luke A, et al. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet 2006;78:410-422.
11. Kathiresan S, Melander O, Anevski D, et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 2008;358:1240-1249.
12. Rader DJ. Illuminating HDL: is it still a viable therapeutic target? N Engl J Med 2007;357:2180-2183.
13. Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007;356:1620-1630.
14. Nissen SE, Tardif J, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356:1304-1316.
15. Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 2008;322:1702-1705. This study demonstrated that a nonsense mutation in apoC-III was associated with an improved lipoprotein profile and decreased coronary artery calcification.
16. Paynter NP, Chasman DI, Buring JE, et al. Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3. Ann Intern Med 2009;150:65-72. This study showed that the use of genetic information for cardiovascular risk prediction did not offer any advantage over the use of serum lipids, CRP, and family history.
17. Mega JL, Morrow DA, Brown A, et al. Identification of genetic variants associated with response to statin therapy. Arterioscler Thromb Vasc Biol 2009;29:1310-1315. This genetic analysis from the PROVE-IT TIMI 22 trial demonstrated that specific isoforms of APOE were associated with a differential response to pravastatin or atorvastatin.
18. *], certain APOE variants were significantly associated with statin response, as well as PCSK9 and HMGCR variants.
19. The SEARCH Collaborative Group; Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy: a genomewide study. N Engl J Med 2008;359:789-799. This study found that 60% of simvastatin-induced myopathy could be attributed to a variant in SLCO1B1, which encodes the organic anion transporter OATP1B1 that is responsible for the hepatic uptake of most statins.
20. *5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009;54:1609-1616. This study found that the effect of SLCO1B1 variants did not signify the same risk of adverse events for all statins.